logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Apr 2019
Tracon Pharmaceuticals, Inc.
Interim analysis results from Phase 3 pivotal TAPPAS trial of TRC105
Angiosarcoma
Q2 2019
Heat Biologics Inc.
Final data from Phase II readout of HS-110
Non Small Cell Lung Cancer (NSCLC)
Q2 2019
Heat Biologics Inc.
Interim data from ComPACT trial of HS-130
Non Small Cell Lung Cancer (NSCLC)
Q2 2019
Celsion Corp.
Data from 1st interim efficacy results from phase III study of ThermoDox (OPTIMA)
primary liver cancer
Late Mar 2019
Dermira Inc.
Top line results Phase 2b dose-ranging study evaluating Lebrikizumab
Moderate-to-severe atopic dermatitis in adult patients
Mar 2019
Alnylam Pharmaceuticals Inc.
Top line results from phase III study of Givosiran (ENVISION trial)
Acute hepatic porphyrias
Early Mar 2019
Insys Therapeutics, Inc.
Results from nonclinical juvenile toxicity study related to naloxone
opioid overdose
Mar 2019
Tracon Pharmaceuticals, Inc.
Preclinical data of TRC105 in combination with checkpoint inhibitors
Cancer
Late Mar 2019
Urovant Sciences Ltd.
Topline results from phase 3 trial of Vibegron (EMPOWUR)
Adults with symptoms of overactive bladder,
28-Feb-2019
Heat Biologics Inc.
New interim data from ongoing phase II trial of HS-110 plus with Opdivo combination
Advanced non-small cell lung cancer (NSCLC)
27-Feb-2019
Sarepta Therapeutics
Results from first 3-patient cohort of phase I/IIa gene transfer clinical trial of MYO-101
Limb-Girdle Muscular Dystrophy Type 2E (beta-sarcoglycanopathy)
20-Feb-2019
Gamida-Cell Ltd.
New data from ongoing phase I study of NAM-NK
Non-Hodgkin lymphoma and multiple myeloma
20-Feb-2019
Gamida-Cell Ltd.
Initial data from a Phase 1/2 study of NiCord
Severe aplastic anemia
15-Feb-2019
Bausch Health Companies Inc.
BHC, BHC.TO
Resubmission of NDA for DUOBRII Lotion
Topical treatment of plaque psoriasis
08-Feb-2019
Catalyst Biosciences Inc.
Data from ongoing Phase 2/3 trial of marzeptacog alfa (MarzAA)
Hemophilia A or B with inhibitors
07-Feb-2019
Protalix BioTherapeutics Inc.
Preliminary pharmacokinetic data from phase III study of Pegunigalsidase alfa (BRIGHT)
Fabry disease
07-Feb-2019
Sangamo Biosciences Inc
Data from Preliminary safety and biochemical changes at up to 4 weeks from Phase 1/2 clinical trial of SB-318
Mucopolysaccharidosis Type I or MPS I in adults
07-Feb-2019
Sangamo Biosciences Inc
Update on safety and biochemical changes at up to 24 weeks from Phase 1/2 clinical trial of SB-913 (CHAMPIONS)
Mucopolysaccharidosis Type II or MPS II in adults
06-Feb-2019
AVROBIO, INC.
Update on phase I study of AVR-RD-01
Fabry disease
05-Feb-2019
AVROBIO, INC.
Update on phase II clinical trial of AVR-RD-01 (FAB-201)
Fabry disease
Feb 2019
SCYNEXIS, Inc.
Top-line data from phase III study of SCY-078 (FURI)
Refractory or intolerant fungal diseases
Feb 2019
Cara Therapeutics Inc.
Preliminary results from pivotal phase III trial of KORSUVA injection (KALM-1)
Hemodialysis patients suffering from moderate-to-severe chronic kidney disease-associated pruritus
18-Jan-2019
TYME TECHNOLOGIES, INC.
Interim data from Stage 1 of phase II trial of SM-88
Pancreatic cancer
18-Jan-2019
Rexahn Pharmaceuticals inc.
Updated data from phase II study of RX-3117 in combination with Abraxane
Newly diagnosed metastatic pancreatic cancer
18-Jan-2019
Rafael Holdings, Inc.
Study plan for phase III trial of Devimistat with modified FOLFIRINOX
First-line treatment for patients with metastatic pancreatic cancer